ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[IMGN]
Reports for Purchase
Showing records 21 - 40 ( 282 total )
Industry: Medical - Drugs
Takeda Partnership to Commercialize ELAHERE in Japan; Raise PT to $27; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Impressive Revenue Bodes Well for Elahere?s Growth; Catalyst-Rich 2023 and 2024; New PT $26; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Pivekimab Showed Safety Advantage and Promising Efficacy Potential in BPDCN; Higher $21 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Homerun From MIRASOL; Potential Full Approval by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Elahere Began 2023 With Strong Sales; MIRASOL Top-Line Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Elahere Launched; MIRASOL Topline in 2Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Key Takeaways From Our Fireside Chat with Dr. Michael Bishop on AML
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Elahere Launched; Pivekizumab Gains Validation; Adjusting PT to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department